Holen Sie sich die Stockscreener-App
74.96
16.89%
-15.23
Handel nachbörslich:
75.10
0.14
+0.19%
Schlusskurs vom Vortag:
$90.19
Offen:
$90.25
24-Stunden-Volumen:
4.62M
Relative Volume:
7.78
Marktkapitalisierung:
$4.33B
Einnahmen:
$76.81M
Nettoeinkommen (Verlust:
$-162.42M
KGV:
-25.07
EPS:
-2.99
Netto-Cashflow:
$-122.49M
1W Leistung:
-17.02%
1M Leistung:
-11.48%
6M Leistung:
+17.27%
1J Leistung:
-17.12%
1-Tages-Spanne:
$71.66
$92.70
1-Wochen-Bereich:
$71.66
$92.91
52-Wochen-Spanne:
$47.86
$96.39
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Vergleichen Sie ACLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
74.96 | 5.22B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma - Seeking Alpha
Guggenheim reiterates Buy rating on Arcellx stock, says weakness overdone - Investing.com India
Citi says Arcellx weakness on ‘highly preliminary’ Kelonia data an overreaction - TipRanks
Why Arcellx Inc Shares Took a Hit Today - TipRanks
Arcellx stock falls after Kelonia reveals promising blood cancer data By Investing.com - Investing.com Canada
Arcellx weakness on competitive worries ‘overdone,’ says Guggenheim - TipRanks
Can Arcellx Inc. stock withstand economic slowdownEarnings Beat & Proven Capital Preservation Methods - newser.com
Arcellx Inc’s Strategic Advantage in Gilead Partnership Drives Buy Rating and $130 Price Target - TipRanks
Risk vs reward if holding onto Arcellx Inc.Weekly Risk Report & Entry Point Confirmation Signals - newser.com
What institutional flow reveals about Arcellx Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Tools to assess Arcellx Inc.’s risk profileWeekly Stock Recap & Expert Verified Stock Movement Alerts - newser.com
How Arcellx Inc. stock performs during Fed tightening cyclesPrice Action & AI Forecasted Entry/Exit Points - newser.com
Is Arcellx Inc. stock a dividend growth opportunityQuarterly Trade Report & AI Driven Stock Movement Reports - newser.com
Why Arcellx Inc. is moving today2025 Price Targets & Daily Market Momentum Tracking - newser.com
Wolfe Research Initiates Coverage of Arcellx (ACLX) with Peer Perform Recommendation - Nasdaq
Arcellx (NASDAQ: ACLX) plans ASH event on Phase 2 iMMagine-1 myeloma trial data - Stock Titan
Arcellx CMO Heery sells $30,600 in ACLX stock By Investing.com - Investing.com South Africa
Arcellx CMO Heery sells $30,600 in ACLX stock - Investing.com India
Arcellx stock initiated at Peerperform by Wolfe Research amid BCMA market competition - Investing.com Nigeria
Arcellx initiated with a Peer Perform at Wolfe Research - TipRanks
Can technical indicators confirm Arcellx Inc.’s reversalGlobal Markets & High Return Stock Watch Alerts - newser.com
Will Arcellx Inc. stock split again soonJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Trend analysis for Arcellx Inc. this weekSwing Trade & Community Trade Idea Sharing - newser.com
Price-Driven Insight from (ACLX) for Rule-Based Strategy - news.stocktradersdaily.com
Using Python tools to backtest Arcellx Inc. strategiesWatch List & Stepwise Entry and Exit Trade Signals - newser.com
Arcellx Inc.: Promising Developments and Strategic Positioning Drive Buy Rating - TipRanks
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):